Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 as Maintenance Therapy in AML Patients Ineligible for Bone Marrow Transplantation
NCT04990102Phase 2Recruiting
- Sponsor
- Georgetown University
- Start
- May 2023
- Primary completion
- Dec 2026
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of daunorubicin + cytarabine liposome in acute myeloid leukemia (AML), sponsored by Georgetown University. Started May 2023; status: recruiting.
02
Drugs
daunorubicin + cytarabine liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04990102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04990102.